Trimurthi has successfully allotted 10,74,000 equity shares upon conversion of warrants, marking a significant capital raising exercise for the pharmaceutical company. The board of directors approved this allotment during their meeting held on December 24, 2025, at the company's registered office in Hyderabad.

Share Allotment Details

The company allotted equity shares with the following specifications:

The shares were issued upon exercising the option available with warrant holders, who had previously paid ₹15.00 per warrant representing 75% of the issue price. These warrants were part of 1,50,00,000 warrants originally allotted on January 10, 2025, on a preferential basis.

Investor Allocation

The allotment was distributed among four strategic investors, comprising both promoter and non-promoter categories:

The allotment represents conversion of 10,74,000 warrants out of the total 1,50,00,000 warrants issued, with 61,91,000 warrants having been converted previously.

Impact on Share Capital

Following this allotment, the company's capital structure has been strengthened significantly:

This represents an increase of ₹1,07,40,000 in the paid-up equity capital, reflecting the company's successful capital expansion through the warrant conversion mechanism.

Regulatory Compliance

The allotment was conducted in full compliance with regulatory requirements. The company had received in-principle approval from BSE Limited on December 31, 2024, and the original warrant issuance was approved through a special resolution passed by shareholders at an Extra-Ordinary General Meeting held on November 18, 2024. The disclosure has been made as per Regulation 30 of SEBI (LODR) Regulations, 2015, ensuring complete transparency in the capital raising process.

The recent allotment of 10.74 lakh equity shares at ₹20 each upon warrant conversion has raised ₹2.15 crores for Trimurthi. This move has increased the company's paid-up capital to ₹17.22 crores, further strengthening its financial position.

Trimurthi (formerly Trimurthi Limited) has announced the execution of a lease deed for laboratory space to establish its research and development facility. The company informed BSE Limited about this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Lease Agreement Details

Trimurthi signed the lease deed with Neovantage Innovation Park Private Limited for laboratory space at the prestigious Genome Valley in Hyderabad, positioning the company in one of India's prominent biotechnology hubs.

Financial Terms and Structure

The lease agreement includes specific financial arrangements designed to accommodate long-term operations. The rental structure incorporates annual escalations to account for market dynamics over the lease period.

Strategic Purpose and Operations

The leased facility will serve as the foundation for Trimurthi's research and development operations. The company plans to establish comprehensive R&D capabilities focusing on pharmaceutical and biotechnology research development, along with formulations.

The laboratory space will enable the company to:

• Conduct pharmaceutical research and development activities
• Pursue biotechnology research initiatives
• Develop new formulations
• Enhance its research capabilities in the pharmaceutical sector

Regulatory Compliance

Trimurthi confirmed that this lease arrangement does not constitute a related party transaction. The company stated that promoters, promoter groups, or group companies have no interest in Neovantage Innovation Park Private Limited, ensuring the transaction maintains arm's length principles.

The company has fulfilled its disclosure obligations under SEBI regulations and requested BSE Limited to disseminate this information through its website for investor awareness.